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Exercise induces a pleiotropic adaptive 
response in skeletal muscle, largely through 
the peroxisome proliferator-activated 
receptor  coactivator 1 (PGC-1). PGC-1 
enhances lipid oxidation and thereby provides 
energy for sustained muscle contraction. Its 
potential implication in promoting muscle 
refueling remains, however, unresolved. Here, 
we investigated a possible role of elevated 
PGC-1 levels in skeletal muscle lipogenesis 
in vivo and the molecular mechanisms that 
underlie PGC-1-mediated de-novo 
lipogenesis. To this end, we studied transgenic 
mice with physiological overexpression of 
PGC-1 and human muscle biopsies pre- and 
post exercise. We demonstrate that PGC-1 
enhances lipogenesis in skeletal muscle 
through liver x receptor  (LXR) dependent 
activation of the fatty acid synthase (FAS) 
promoter and by increasing FAS activity. 
Using chromatin immunoprecipitation, we 
establish a direct interaction between PGC-1 
and the LXR-responsive element in the FAS 
promoter. Moreover, we show for the first 
time that increased glucose uptake and 
activation of the pentose phosphate pathway 
provide substrates for RNA synthesis and 
cofactors for de-novo lipogenesis. Similarly, 
we observed increased lipogenesis and lipid 
levels in human muscle biopsies that were 
obtained post-exercise. Our findings suggest 
that PGC-1 coordinates lipogenesis, 
intramyocellular lipid accumulation and 
substrate oxidation in exercised skeletal 
muscle in vivo. 
 
 
Over the last century, people have become 
increasingly sedentary. This development has 
resulted in a marked rise in the prevalence of  
 
metabolic disorders (1). Inversely, exercise is an 
excellent intervention in metabolic diseases. 
However, the molecular mechanisms that 
underlie the health beneficial effects of exercise 
are unclear. 
Chronic endurance exercise elicits substantial 
adaptations in skeletal muscle, including changes 
in metabolic and myofibrillar properties (2). The 
peroxisome proliferator-activated receptor  
coactivator 1 (PGC-1) is a crucial regulator of 
this adaptive response (3-5). Accordingly, 
exercise leads to a rapid and marked increase in 
PGC-1 levels in skeletal muscle (6,7). 
Subsequently, PGC-1 interacts with a broad 
range of different transcription factors (8) and 
thereby promotes adaptive processes (9,10). 
Chronic PGC-1 induction drives fiber-type 
switching from fast, glycolytic towards slow, 
oxidative fibers (11), increases aerobic work 
performance (12) and confers higher resistance 
to fatigue in skeletal muscle preparations ex vivo 
(11). Interestingly, muscle-specific over-
expression of PGC-1 per se, even in the 
absence of physical activity or a functional motor 
neuron, is sufficient to drive these changes, 
which are typical of regular endurance training 
(11-13).  
 
Higher intramyocellular lipid (IMCL) content is 
observed in endurance athletes and constitutes a 
typical adaptation to chronic endurance exercise 
(14). These lipids are recruited as energy source 
during prolonged physical activity (15,16). 
While a central role for PGC-1 in enhancing 
lipid catabolism is well established (9,10), it is 
currently not known whether elevated PGC-1 
affects lipid anabolism in trained skeletal muscle 
in vivo. A recent in-vitro study in myoblasts 
suggested that adenoviral over-expression of 
PGC-1 is paralleled by increased gene 
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expression of fatty acid synthase (17). Thus, 
PGC-1 might play a role in muscle lipid 
refueling, at least in a cell culture model under 
hyperglycemic conditions (17). Currently, it is 
unresolved whether PGC-1 can induce FAS 
transcription in vivo, whether there is a direct 
relationship between activation of PGC-1 and 
lipogenesis, how this could be brought about 
mechanistically and how this process is fueled. 
 
We therefore studied the effect of stably elevated 
muscle PGC-1 levels on de-novo lipogenesis in 
vivo in a transgenic mouse model that allows the 
dissociation between the consequences of 
elevated muscle PGC-1 and other confounding 
factors induced by exercise (11). In particular, 
we have tested the effect of PGC-1α on fatty acid 
synthase (FAS), the multifunctional enzyme that 
catalyzes all seven reactions of de-novo 
lipogenesis, as well as on glucose-6-phosphate 
dehydrogenase, the rate-limiting enzyme of the 
pentose phosphate pathway. The latter produces 
NADPH, which serves as reducing agent for 
lipogenesis. Moreover, we investigated the 
molecular mechanisms that underlie these 
adaptations. We focused our efforts on the 
function of PGC-1 in vivo in the extensor 
digitorum longus muscle (EDL), which 
represents a typical glycolytic muscle that 
naturally expresses low levels of PGC-1 (7,11). 
Gain-of-function of PGC-1 in EDL muscle 
results in PGC-1 protein levels that are 
comparable to those normally observed in 
oxidative muscles (11). The main findings of this 
study in the PGC-1 muscle-specific transgenic 
mouse model were subsequently validated in 
human muscle biopsies that were obtained pre- 
and post-exercise. 
 
Materials and Methods 
 
Animals 
MPGC-1 TG mice (11) and control littermates 
were maintained in a conventional facility with a 
fixed 12-h light/dark cycle on a commercial 
pelleted chow diet and free access to tap water. 
Studies were performed according to criteria 
outlined for the care and use of laboratory 
animals and with approval of the Swiss 
authorities. 
 
Human muscle biopsies 
Human biopsies were obtained from vastus 
lateralis muscle in the course of a previously 
published study (18). All volunteers gave their 
written consent to participate in the study and the 
experiments were approved by the ethics 
committee of the University of Bern. In brief, all 
subjects trained on an electrically braked cycle 
ergometer at a constant load during 30 minutes 
per day, 5 days per week for a total of 6 weeks 
with 85% of maximal heart rate after 10 minutes 
of exercise and lactate levels between 4-6mmol/l. 
Biopsies were taken from vastus lateralis muscle 
before and after the 6-wk training period using 
the Bergstrom technique. Muscle tissue was 
immediately frozen in liquid nitrogen, and stored 
at -80°C for later RNA extraction. 
 
Lipid quantification by electron microscopy 
Quantification of muscle lipids was performed as 
described previously (19).  
Glutaraldehyde-fixed samples were dehydrated 
in increasing ethanol concentrations and 
embedded in Epon. After cutting ultrathin 
sections (50–70 nm) on a LKB Ultrotome III, 
uranyl acetate and lead citrate staining was 
performed. The sections were then photographed 
and examined. We analyzed 15 micrographs of 
one section per animal.  
 
RNA extraction and RT-PCR 
Frozen tissues were homogenized under liquid 
nitrogen and total RNA was isolated using Trizol 
reagent (Invitrogen). RNA concentrations were 
adjusted and reverse transcription was carried out 
using random hexamer primers (Promega). Real-
time PCR analysis (Power SYBR Green Master 
Mix, Applied Biosystems) was performed using 
the ABI Prism 7000 Sequence Detector. Relative 
expression levels for each gene of interest were 
calculated with the Ct method and normalized 
to the expression of the Tata box binding protein 
(TBP). Primer sequences are listed in 
Supplementary Table T1. 
 
De-novo lipogenesis 
De-novo lipogenesis was assayed according to 
the method of Stansbie et al. (20). In brief, 3H2O 
(25μCi/g bw) were injected intraperitoneally and 
1h later the animals were sacrificed. Muscles 
were dissected, saponified in ethanolic KOH, and 
acidified with H2SO4. Fatty acids were extracted 
with light petroleum and radioactivity was 
quantified using a Beckman liquid scintillation 
counter. The contralateral muscle was used to 
assay the incorporation of tritium into different 
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Glucose uptake was determined using tritium 
labeled 2-deoxyglucose (Amersham Biosciences) 
according to the protocol of Hansen at al. (22). 
Radioactivity was quantified using a Beckman 
liquid scintillation counter. 
All values were corrected for initial tissue weight 
and expressed as fold change compared to 
control animals. 
 
Muscle metabolites (NADP, NADPH, 
Glutathione, ROS, glucose-6-phosphate) 
NADP and NADPH levels were assessed 
colorimetrically using EnzyChrom 
NADP+/NADPH Assay Kit from BioAssay 
Systems. Reduced, oxidized and total glutathione 
levels were determined using Glutathione Assay 
Kit from BioVision Research products. Glucose-
6-phosphate was determined as described by 
Wende et al. (23). 
 
Enzymatic activities 
Muscles were dissected, immediately frozen in 
liquid nitrogen and homogenized under liquid 
nitrogen. Fatty acid synthase (FAS) activity was 
measured photometrically according to the 
method described by Pénicaud et al. (24). 
Glucose 6-phosphate dehydrogenase (G6PDH) 
activity was determined according to the method 
of Ninfali et al. (25).  
 
Incorporation of glucose into macromolecules 
Incorporation of [6-3H] glucose (Amersham 
Biosciences) into RNA and DNA was measured 
according to the method described by Glazer and 
Weber (26). 
 
Cell culture experiments 
Mouse C2C12 myoblasts were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum in an 
atmosphere of 5% CO2 in subconfluent culture. 
For reporter gene assays, C2C12 myoblasts were 
transfected using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s 
instructions. Renilla luciferase was used for 
normalization. Cells were harvested 24 hrs after 
transfection and luciferase activity was measured 
using Dual-Glo Luciferase assay (Promega). 
LXR siRNA was purchased from Santa Cruz. 
C2C12 myoblasts were differentiated into 
myotubes and then infected with adenoviral 
vectors for murine green fluorescent protein 
(GFP) or GFP- PGC-1. 
 
 
Chromatin Immunoprecipitation (ChIP) assay 
ChIP assays were performed using ChIP-IT 
Express (Active Motif) according to the 
manufacturer’s instructions. Chromatin was 
subjected to immunoprecipitation using anti-
PGC-1 antibodies (PGC-1 (H-300), Santa 
Cruz) or unrelated IgG bound to protein G-
coupled magnetic beads. Precipitated DNA was 
recovered and amplified by RT-PCR with 
primers flanking the LXRE or SREBP binding 
site, respectively. 
 
Data analysis and statistics 
All data are presented as means ± SE. The data 
were analyzed by 2-tailed, unpaired Student’s t 
test or Mann-Whitney test when the difference 
between the two SDs was significantly different. 
For the analyses of human samples, 2-tailed, 
paired Student’s t test was used. Levels of 
significance are indicated as follows: *** 
p<0.001, ** p< 0.01, * p< 0.05. 
For the analysis of reporter gene assays, two-
factor ANOVA was performed. Post hoc 
pairwise comparison was done by unpaired 




Elevated de-novo lipogenesis and lipid 
accumulation in glycolytic muscle of MPGC-1 
TG mice 
 
We first tested whether PGC-1 affects gene 
expression and/or activity of skeletal muscle 
fatty acid synthase (FAS) in vivo. MPGC-1 TG 
mice show higher levels of FAS expression 
(+50%, P<0.05) (Figure 1A) and enzymatic 
activity (+131%, P<0.001) (Figure 1B) in 
skeletal muscle than their control littermates 
along with increased de-novo lipogenesis (+44%, 
P<0.01) (Figure 1C) and elevated 
intramyocellular lipid content (+157%, P<0.01) 
(Figure 1D). Detailed analysis of the different 
lipid components revealed higher levels of de-
novo synthesized free fatty acids and 
triglycerides in skeletal muscle of MPGC-1 TG 
mice (Supplementary Figure 1A and B). Since 
muscle often contains interspersed adipose cells 
that express high levels of FAS and show high 
rates of lipogenesis, we validated FAS 
expression, activity and de-novo lipogenesis in 
cultured skeletal muscle cells overexpressing 
PGC-1α. As observed in muscle in vivo, PGC-1α 
also increases FAS mRNA expression, activity 
and de-novo lipogenesis directly in muscle cells 
(Supplementary Figure 2A, B and C).  
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To test whether mRNA levels of genes involved 
in lipid uptake are concomitantly altered in 
MPGC-1 TG mice, we quantified the mRNA 
levels of lipoprotein lipase (LPL), cluster of 
differentiation 36 (CD36), plasma membrane 
fatty acid binding protein (FABPpm) and 
different fatty acid transporter proteins (FATPs). 
Of those, only CD36, FABPpm and FATP4 are 
significantly elevated in transgenic animals 
(Figure 1E). Then, we determined the level of 
acetyl-CoA synthase (ACS), which activates 
imported lipids by linking them to Coenzyme A. 
ACS mRNA expression is not different between 
control and transgenic animals (Figure 1E). 
Finally, expression of genes implicated in fatty 
acid esterification, namely acetyl-
CoA:diacylglycerol transferase 1 (DGAT1) and 
mitochondrial glycerol-3-phosphate 
acyltransferase (mtGPAT) are increased in 
MPGC-1 TG mice (+51% and +150% 
respectively, P<0.05) (Figure 1E) while other 
mediators of lipid synthesis, such as lipin, remain 
unaltered (Supplementary Figure 3). 
 
PGC-1 directly regulates the FAS promoter 
through coactivation of the Liver X Receptor  
Retinoid X Receptor  (LXR/RXR 
 
As a consequence of the elevated FAS 
transcription in MPGC-1 TG animals (Figure 
1A), a possible regulatory effect of PGC-1 on 
the FAS proximal promoter was investigated. 
Our data indicate that PGC-1increases FAS 
promoter activity and that this effect of PGC-1 
is potentiated by the concomitant expression of 
LXR/RXR, but not of SREBP1c (Figure 2A). 
Silencing of LXR or deletion of the LXR-
responsive element in the FAS promoter 
(ΔLXRE) abrogate the effect of PGC-1 on FAS 
transcription (Figure 2B). In contrast, mutation 
of the SREBP1c binding site did not reduce the 
effect of PGC-1 on LXR/RXR-induced FAS 
transcription (Supplementary Figure 4). 
Moreover, LXR RXR and RXRβ expression 
levels are significantly elevated, while the sterol 
responsive element binding protein 1c 
(SREBP1c) is unaltered in skeletal muscle of 
MPGC-1 TG animals (Figure 2C). Using 
chromatin immunoprecipitation (ChIP) followed 
by RT-PCR we demonstrate that in MPGC-1 
TG animals PGC-1 is enriched in the LXRE of 
the FAS proximal promoter (Figure 2D). In 
contrast, PGC-1 was not recruited to the 
SREBP binding site in the FAS promoter of 
MPGC-1 TG and control animals (Figure 2D). 
 
Increased glucose utilization in glycolytic 
muscle of MPGC-1 TG mice 
 
Besides FAS activation, important cofactors for 
lipid biosynthesis need to be delivered through 
glucose metabolism and sustained glucose 
uptake is required for lipogenesis to proceed. We 
analyzed different key steps of glucose uptake at 
the transcriptional level as well as glucose uptake 
directly. Gene expression of GLUT4, the main 
insulin-sensitive glucose transporter in muscle, 
and hexokinase 2, the enzyme used to trap 
glucose in muscle, is higher in MPGC-1 TG 
mice compared to controls (+50% and +93% 
respectively, P<0.05) while expression of the 
second major glucose transporter in muscle 
(GLUT1) is unchanged (Figure 3A). Moreover, 
glucose uptake as measured by the intracellular 
accumulation of tritiated deoxyglucose is 
elevated in MPGC-1 TG animals (+48%, 
P<0.05) (Figure 3B). 
 
Enhanced glucose-6-phosphate dehydrogenase 
activity in MPGC-1TG mice 
 
We speculated that increased glucose uptake in 
MPGC-1 TG mice leads to intracellular 
accumulation of glucose-6-phosphate (G6P). 
Indeed, MPGC-1 TG mice show higher levels 
of muscle G6P than their control littermates 
(Supplementary Figure 5A). G6P 
concomitantly serves as initial substrate and 
thereby as an activator of the pentose phosphate 
pathway. Thus, we measured the expression and 
enzymatic activity of glucose-6-phosphate 
dehydrogenase (G6PDH). PGC-1 gain-of-
function does not affect G6PDH gene expression 
(Figure 3C), but leads to increased enzymatic 
activity (+158%, P<0.05) (Figure 3D). To 
validate whether PGC-1α increases G6PDH 
activity in muscle cells, we assessed G6PDH in 
isolated muscle cells overexpressing PGC-1α. 
Similar to our findings in muscle in vivo, PGC-
1α augments G6PDH activity directly in muscle 
cells (Supplementary Figure 5B). 
 
Increased synthesis of NADPH, GSH and 
ribose-5-phosphate in MPGC-1 TG mice 
 
The pentose phosphate pathway is the major 
anaplerotic pathway of NADPH. NADPH serves 
as reducing agent for glutathione and is 
furthermore required for de-novo lipogenesis. 
Thus, consistent with the higher G6PDH activity 
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in muscle of MPGC-1 TG mice, we found 
significantly elevated NADPH with a parallel 
reduction in NADP+ concentration compared to 
controls (Figure 4A and B) (P<0.05 for both). 
Consequently, we also observed higher levels of 
total and reduced glutathione (Figure 4C and D) 
in MPGC-1 TG mice (P<0.05). In contrast, the 
amount of oxidized glutathione is similar in 
MPGC-1 TG and control animals (Figure 4E). 
 
In addition to its role for NADPH and 
glutathione production, the pentose phosphate 
pathway plays a crucial role in nucleotide 
biosynthesis by producing ribose-5-phosphate. 
Therefore, tritium labeled glucose was used to 
test whether glucose diverted toward the pentose 
phosphate pathway is partially incorporated into 
nucleotides as ribose-5-phosphate. While tritium 
labeled glucose is used as a substrate for RNA 
synthesis in MPGC-1 TG mice (+65%, P<0.05) 
(Figure 4F), no changes are observed for 
incorporation of glucose metabolites into DNA 
(Figure 4G). Furthermore, gene expression of 
ribonucleotide reductase, a transcriptionally 
regulated gene involved in converting 
ribonucleotides to deoxy-ribonucleotides, is not 
different between MPGC-1 TG mice and 
control littermates (Figure 4H). 
 
Improved capacity for de-novo lipogenesis in 
endurance athletes 
 
Endurance athletes display high levels of 
intramyocellular lipids; however, the origin of 
these lipids is unknown. Similar to the MPGC-
1 TG animals, FAS gene expression is elevated 
in human muscle post exercise (Figure 5A). 
Importantly, the induction of FAS gene 
expression is paralleled by an increased level of 
intramyocellular lipids (Figure 5B) after 6 weeks 
of endurance training. In contrast, ACS levels are 
not altered in human muscle post exercise 
(Figure 5C). Consistent with our mouse date 
(Figure 2C), we observed elevated LXR and 
RXR levels in human muscle biopsies post 
exercise (Figure 5D and E). RXRβ levels were 
not altered (Figure 5F). Moreover, in line with 
our mouse data, Glut4 and hexokinase 2 levels 
were elevated post-exercise in human muscle, 
while G6PDH levels were unchanged 





Elevated intramyocellular lipids are a hallmark 
of type 2 diabetic muscle and contribute to 
harmful effects on glucose homeostasis and 
insulin sensitivity (27,28). However, endurance 
athletes, which are highly insulin sensitive, also 
display elevated IMCL levels, a phenomenon 
referred to as the “athlete’s metabolic paradox” 
(29,30). The difference in the molecular 
mechanisms between the IMCL accumulation in 
exercise and diabetes is poorly defined. We now 
show that de-novo lipogenesis in skeletal muscle 
contributes to the elevated intramyocellular lipid 
content in muscle-specific PGC-1 transgenic 
mice, a genetic model for elevated endurance 
capacity, and importantly, also in human 
endurance athletes. We demonstrate in vivo that 
PGC-1 mediates accumulation of IMCL by 
recruiting the lipogenic machinery in muscle, 
specifically by inducing the expression and 
activity of FAS, a multifunctional enzyme that 
catalyzes all seven reactions required for de-novo 
lipid biosynthesis. In combination, PGC-1 
increases the expression of genes encoding lipid 
esterification proteins (namely DGAT and 
mtGPAT) and thereby allows the coordinate 
synthesis and subsequent accumulation of 
intramyofibrillar lipids. Moreover, we provide 
novel insights into the molecular mechanisms by 
which PGC-1 directly promotes FAS 
transcription by inducing and coactivating the 
nuclear receptor LXR on the proximal FAS 
promoter. Taken together, these findings 
demonstrate for the first time a direct role of 
PGC-1 in muscle de-novo lipogenesis and 
intramyocellular lipid accumulation in vivo. 
 
The absence of transcriptional response of key 
genes for lipid uptake and activation implies that 
the uptake of fatty acids plays a minor role for 
accumulation of IMCL compared to de-novo 
lipogenesis. Of all the genes that we studied, 
only CD36 and FABPpm were significantly 
induced in the MPGC-1 TG mice. However, in 
addition to their function at the cell membrane, 
these two genes have been associated with 
mitochondrial lipid oxidation and mitochondrial 
aspartate metabolism, respectively (31,32) and 
thus might be more relevant as mitochondrial 
enzymes in this context. An important role for 
muscle de-novo lipogenesis in the accumulation 
of intramyocellular lipids as opposed to lipolysis 
of triglycerides from adipose tissue, transport of 
fatty acids to the muscle und subsequent lipid 
import is further substantiated by previous 
studies showing unaltered fat mass, dietary lipid 
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intake and circulating lipid levels in MPGC-1 
TG mice on regular chow or high fat-containing 
diet (12,33).  
Moreover, the mRNA levels of ACS, an enzyme 
which is indispensable to activate imported 
lipids, but which is not required for de-novo 
lipogenesis, are unaltered in MPGC-1 TG 
compared to wild-type mice and in human 
muscle biopsies pre vs. post exercise, 
respectively. Finally, a direct functional analysis 
performed in muscle cells revealed that over-
expression of PGC-1 reduces lipid import (17). 
Together, these data suggest that de-novo 
lipogenesis takes precedence over lipid import 
for the generation of IMCL in muscle, at least in 
our experimental setting. Thus, the cause of 
IMCL accumulation in trained muscle might 
differ from that in type 2 diabetes, which could 
be more dominantly driven by lipid uptake (34). 
 
According to the classic hypothesis by Randle, 
lipid and glucose oxidation mutually regulate 
each other in a negative manner (35,36). 
Consistently, it has been found that the elevation 
of β-oxidation by PGC-1 in muscle-specific 
transgenic animals is accompanied by a 
reduction in glycolysis and glucose oxidation. 
Moreover, the increase in glucose uptake 
mediated by PGC-1 can only partially be 
explained by glycogen synthesis, since even in 
muscles fully loaded with glycogen, muscle-
specific PGC-1 transgenic mice retain higher 
glucose uptake (23). Here, we demonstrate that 
PGC-1 induces glucose uptake in order to 
enhance the glucose flux through the pentose 
phosphate pathway as a prerequisite to produce 
the NADPH that is required as the reducing 
agent for de-novo lipogenesis. Furthermore, 
ribose-5-phosphate is made for nucleotide 
synthesis, and the subsequent increase in mRNA 
transcription that is strongly promoted by PGC-
1. While previous studies observed elevated 
G6PDH activity in skeletal muscle following 
exercise (37), we now provide evidence that 
G6PDH activation and the parallel increase in 
FAS and IMCL are driven by PGC-1. 
 
Interestingly, PGC-1 muscle-specific 
transgenic animals exhibit a higher susceptibility 
to develop insulin resistance when fed a high-fat 
diet (33). This seems paradoxical, since these 
animals exhibit all features of trained animals 
(11,12) and exercise is known to improve insulin 
sensitivity in muscle (38). Our findings could 
now explain this ostensible discrepancy by the 
direct effect of elevated PGC-1 on de-novo 
lipogenesis and lipid accumulation. In MPGC-1 
TG animals, lipids accumulate due to the high-fat 
diet and in addition, due to de-novo lipogenesis 
that is promoted by the ectopic PGC-1. 
Moreover, despite their elevated oxidative 
capacity, these mice are sedentary when kept in 
standard animal cages and lipid turnover in 
skeletal muscle is accordingly low compared to 
an active animal. Similarly, athletes that undergo 
training cessation often experience perturbations 
in insulin sensitivity and glucose homeostasis 
(39-41). These periods of relative insulin 
resistance are preceded by a reduction in PGC-
1, CPT-1b and citrate synthase gene expression 
along with reduced mitochondrial lipid oxidation 
(42). Reduced muscle lipid oxidation in 
combination with elevated IMCL, i.e. a low 
turnover of lipids, mirrors the metabolic profile 
of type 2 diabetes (43). Our findings have highly 
relevant implications for the development of so-
called exercise mimetics, pharmaceutical 
interventions aimed at mirroring the plastic 
adaptations of muscle to exercise (44,45). If 
these compounds are true exercise mimetics, 
they will also promote de-novo lipogenesis and 
thus increase the susceptibility for unwanted side 
effects, in particular with a high fat, Western diet 
and lack or cessation of actual exercise. 
Therefore, as a monotherapy, such 
pharmaceuticals are not likely to constitute a 
valid alternative to real exercise (46,47). 
 
In conclusion, we provide new evidence that 
PGC-1 promotes lipid anabolism in vivo by 
stimulating pentose phosphate pathway activity, 
de-novo lipid biosynthesis and IMCL 
accumulation, which can serve as substrates for 
subsequent physical activity (Figure. 6). In 
addition, we provide first insights into the 
molecular mechanisms that underlie PGC-1-
driven de-novo lipogenesis in skeletal muscle. 
These metabolic adaptations are highly 
advantageous for trained muscle due to the tight 
coordination of energy demand and supply. Our 
data highlight novel approaches as well as 
pitfalls for the therapy of metabolic diseases that 
are associated with a sedentary life-style. 
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Figure Legends 
 
Figure 1. Enhanced lipid anabolism in EDL muscle of MPGC-1 TG animals. 
(A-D) FAS gene expression (A), activity (B), de-novo lipogenesis (C) and accumulation of 
intramyofibrillar lipids (D) in glycolytic muscle of MPGC-1 TG vs. wild type animals. 
Abbreviations: FAS, fatty acid synthase. 
(E) Relative expression of genes involved in fatty acid uptake (LPL, CD36, FABPpm and FATPs), 
fatty acid activation (ACS) and esterification (DGAT and mGPAT). Abbreviations: LPL, lipoprotein 
lipase; CD36, cluster of differentiation 36; FABPpm, plasma membrane fatty acid binding protein; 
FATP, fatty acid transporter protein; ACS, acetyl-CoA synthase; DGAT, acetyl-CoA:diacylglycerol 
transferase; mtGPAT, mitochondrial glycerol-3-phosphate acyltransferase. 
All values are expressed as means ±SE (n =6-8 per group); * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 2. LXR-dependent activation of the FAS promoter. 
(A) FAS promoter activity following transfection of myoblasts with pcDNA (empty vector) (black 
bars) or PGC-l (grey bars) and in response to cotransfection with LXR/RXR or SREBP1c 
expression plasmids. 
Values are expressed as means ±SE (n =6 per group); Effect of PGC-l: @@@ p<0.001; effect of 
LXR/RXR or SREBP1c: ### p<0.001; interaction: §§ p<0.01, as assessed by two-factor ANOVA. 
(B) FAS promoter activity following transfection of myoblasts with pcDNA (empty vector) (black 
bars) or PGC-l (grey bars) and in response to silencing of LXR or deletion of the LXR-responsive 
element (ΔLXRE). 
(C) Relative expression of genes involved in FAS promoter activation in muscle of MPGC-1 TG 
mice vs. controls. All values are expressed as means ±SE (n =6-8 per group); * p<0.05; ** p<0.01. 
(D) ChIP assays on mouse skeletal muscle. Recruiting of PGC-l to LXRE and SRE binding sites in 
the FAS promoter of MPGC-1 TG mice and control animals, respectively. All values are expressed 
as means ±SE (n =4 per group); ** p<0.01. 
Abbreviations: LXR, liver X receptor; RXR, retinoid X receptor; SREBP1c, Sterol responsive element 
binding protein 1c; LXRE, LXR responsive element; SRE, SREBP responsive element. 
 
Figure 3. Enhanced glucose uptake and pentose phosphate metabolism in EDL muscle of 
MPGC-1 TG mice.  
(A) Relative gene expression of GLUT1 (glucose transporter 1), GLUT4 (glucose transporter 4) and 
HK2 (hexokinase 2) in EDL as measured by RT-PCR and expressed as fold change over controls. 
(B) Glucose uptake in EDL muscle. 
(C and D) Determination of glucose 6-phosphate dehydrogenase (G6PDH) mRNA levels (C) and 
activity (D) in glycolytic muscle of MPGC-1 TG and control mice. 
All values are means ±SE (n =6-8 per group). * p<0.05. 
 
Figure 4. Increased pentose phosphate pathway products in MPGC-1 TG mice.  
(A and B) Concentrations of NADPH (A) and NADP+ (B) in glycolytic muscle of MPGC-1 TG mice 
vs. controls. 
(C-E) Amounts of total (C), reduced (GSH) (D) and oxidized (GSSG) (E) glutathione extracted from 
glycolytic muscle. 
(F and G) Incorporation of tritium labeled glucose into RNA (F) and DNA (G) in EDL of MPGC-1 
TG mice and control animals. 
(H) Determination of ribonucleotide reductase (RiboRed) mRNA levels. 
All values are means ±SE. (n=6-8 per group). * p<0.05. 
 
Figure 5. Higher FAS expression and IMCL in endurance athletes. 
(A-C) FAS mRNA expression (A), intramyocellular lipids (B) and ACS mRNA expression (C) in 
human endurance athletes before and after 6 weeks of high intensity endurance exercise.  
(D-F) Relative expression of LXR, RXR and RXRβ in human muscle biopsies pre- and post-
exercise. Mean values are expressed as bars with SE (n=6). * p<0.05 as assessed by paired t-test. 
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Figure 6. PGC-1 coordinates anabolic and catabolic pathways in skeletal muscle. 
A model integrating the findings of this study and showing the PGC-1-mediated coordination of de-
novo lipogenesis, lipid accumulation and lipid oxidation. Enzymes being activated by PGC-1 and 
regulating metabolic key steps are indicated in grey circles (G6PDH, FAS, CPT-1b). PGC-1 
coordinates anabolic processes (lipogenesis and IMCL accumulation) and catabolic processes (β-
oxidation, Krebs cycle and OXPHOS) in skeletal muscle. PGC-1 enhances glucose uptake and flux 
through the pentose phosphate pathway. Concomitantly, NADP+ is reduced to NADPH, which serves 
as reducing agent for lipogenesis. De-novo synthesized fatty acids are then stored as IMCL and serve 
as energy substrate during endurance exercise. By metabolizing lipids through β-oxidation, Krebs 
cycle and OXPHOS, ATP for muscle contraction is produced. Fluxing glucose towards the pentose 
phosphate pathway also generates ribose-5-phosphate with constitutes a structural element of ATP and 
other nucleotides. Abbreviations: Glu, glucose; GLUT, glucose transporter; G6PDH, glucose 6-
phosphate dehydrogenase; NTP, nucleotide triphosphate; ATP, adenosine triphosphate; NADPH, 
reduced nicotinamide adenine dinucleotide phosphate; GSH, reduced glutathione, GSSG, oxidized 
glutathione; FAS, fatty acid synthase; FA, fatty acids; IMCL, intramyofibrillar lipids; CPT-1b, 
carnitine palmitoyl transferase 1b; OXPHOS, oxidative phosphorylation. 
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